Labcorp Holdings Flags CMS 2027–29 Payment Cuts; Reaffirms 2026–29 Outlook

What Happened
Labcorp Holdings Inc. (LH) filed an 8-K on Sept. 22, 2026, disclosing that the Centers for Medicare & Medicaid Services (CMS) released preliminary Clinical Laboratory Fee Schedule payment rates for 2027–2029 on Sept. 21, 2026. Labcorp says the CMS rates appear based on data not fully representative of the commercial lab market and would cause steep annual payment cuts that could threaten patient access. The company reiterated support for the bipartisan RESULTS Act as a legislative solution and reaffirmed the long-term 2026–2029 outlook it announced at its Investor Day on Sept. 10, 2026.

Key Details

• CMS preliminary payment rates released Sept. 21, 2026; Labcorp filed the disclosure Sept. 22, 2026.
• Reaffirmed 2026–2029 outlook:
  • Compound annual revenue growth: 5%–8%
  • Adjusted operating margin expansion: 75–150 basis points by end of 2029
  • Compound annual adjusted EPS growth: 8.5%–11.5%
  • Compound annual free cash flow growth: in line with adjusted earnings growth
• Labcorp will evaluate CMS rates and expects to update on the impact to 2027 guidance when it issues full 2027 guidance in February 2027.
• Company notes use of non‑GAAP adjusted measures and says it cannot provide forward-looking reconciliations for those adjusted measures.

Why It Matters
This filing signals potential reimbursement pressure from Medicare fee changes (PAMA-related) that could affect Labcorp’s revenue and margins in coming years. Management has already baked PAMA pressure into its provided 2026–2029 outlook but will quantify 2027 guidance impacts in February 2027. Retail investors should watch upcoming guidance and legislative developments (e.g., the RESULTS Act) because changes to Medicare lab payment policy could materially affect Labcorp’s financial results and cash flow.